Roche pins Tarceva hope on Cancer Drugs Fund after NICE rejects appeal
This article was originally published in Scrip
Roche says it hopes that its anticancer drug Tarceva (erlotinib) will be available in England through the Cancer Drugs Fund as a monotherapy for maintenance treatment for some non-small cell lung cancer patients. Following a failed appeal from the company, NICE, the health technology appraisal body for England and Wales, issued final and binding guidance rejecting the drug on 29 June because of doubts over the overall survival gain that the drug offers.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.